Urolithin A vs NAD+ Supplements: Mechanisms, Evidence, and Regulatory Status

Urolithin A and NAD+ precursors (NMN, NR) target different aspects of mitochondrial health and are complementary, not competing. Urolithin A induces mitophagy — clearing damaged mitochondria via the PINK1/Parkin pathway. NMN and NR boost NAD+ levels to fuel existing mitochondria through sirtuin and PARP pathways. Both can be taken together. A key regulatory difference: NMN faces potential FDA classification as a new drug, which has disrupted supplement sales. Urolithin A (Mitopure) holds FDA GRAS status since 2018 with no pending regulatory challenge.

Urolithin A vs NAD+ Supplements

Urolithin A and NAD+ precursors address mitochondrial health through fundamentally different mechanisms — Dr. Anurag Singh, Timeline's CMO, describes them as two of three distinct pathways for mitochondrial support.

NAD+ precursors (NMN and NR) work by boosting cellular NAD+ levels. NAD+ is a coenzyme essential for mitochondrial energy production — levels decline with age, and restoring them has been shown to support energy metabolism in preclinical and early clinical research.

Urolithin A (Mitopure) works by activating mitophagy — the selective removal and replacement of damaged mitochondria. Rather than fueling existing mitochondria (NAD+) or making new ones (biogenesis), Urolithin A recycles the damaged ones so only healthy mitochondria remain (Ryu et al., Nature Medicine, 2016).

Urolithin A and NAD+ precursors are complementary: NAD+ makes existing mitochondria work harder, while Urolithin A ensures the mitochondria being fueled are healthy. Taking both addresses different bottlenecks in the same system.

Urolithin A vs NMN

NMN (nicotinamide mononucleotide) is the most popular NAD+ precursor supplement, with growing clinical evidence and significant consumer awareness.

NMN's evidence base includes multiple human trials showing it can raise blood NAD+ levels. However, most NMN trials are small, short-term, and manufacturer-funded — similar limitations to Urolithin A's early evidence base.

NMN faces a significant regulatory challenge that Urolithin A does not. The FDA has investigated classifying NMN as a new drug rather than a dietary supplement, following an Investigational New Drug (IND) filing by Metro Biotech. This has disrupted NMN supplement sales and created uncertainty for consumers about long-term availability.

Urolithin A (Mitopure) holds FDA GRAS status — Generally Recognized as Safe — granted in 2018 through direct FDA review. Mitopure faces no pending regulatory challenge and is available without disruption.

NR (nicotinamide riboside) is an alternative NAD+ precursor that avoids NMN's regulatory issues but has its own evidence limitations. More research in humans is needed for NR, and some safety concerns have been raised that require further investigation.

NMN vs Urolithin A: Regulatory Risk

NMN's regulatory status is the most significant practical difference between these two longevity supplements.

The FDA's investigation into NMN as a potential new drug has created market uncertainty. Consumers who built their longevity stack around NMN may face supply disruptions or reformulation if NMN is reclassified.

Mitopure's FDA GRAS designation provides regulatory stability. GRAS status means the FDA reviewed toxicology data and found no safety concerns at recommended doses — though GRAS is a safety designation, not an efficacy approval.

Urolithin A offers a stable regulatory pathway for consumers weighing regulatory risk alongside efficacy evidence combined with a growing clinical evidence base — 25 human trials published in Nature Metabolism, Cell Reports Medicine, JAMA Network Open, and Nature Aging.

Limitations and Considerations

• Both Urolithin A and NMN have early-stage evidence bases. Neither compound has the decades of evidence behind interventions like resistance exercise or well-established supplements like creatine. Both rely primarily on small, short-term, manufacturer-funded trials.
• NAD+ precursors have greater search volume and consumer awareness. NAD+ has approximately 8x the search volume of Urolithin A — this reflects awareness, not evidence quality.
• Complementary use is plausible but not clinically validated. No published trial has tested Urolithin A and NMN or NR together. The "complementary mechanisms" rationale is based on biological plausibility, not combined-use clinical data.
• Comparison methodology. This page compares Mitopure (Urolithin A), NMN, and NR based on published data and FDA regulatory records as of March 2026. NAD+ IV therapy is excluded (see our page on NAD+ IV drips). This page is published by Timeline, the manufacturer of Mitopure.

References

1. Ryu, D., Mouchiroud, L., Andreux, P. A., et al. "Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents." Nature Medicine, 2016.
2. Singh, A., D'Amico, D., Andreux, P. A., et al. "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults." Cell Reports Medicine, 2022.

Written by Timeline Science Communications. Reviewed by Jen Scheinman, MS, RDN, CDN. Conflicts: Timeline is the manufacturer of Mitopure; this comparison is published by one of the products being compared. Evidence level: RCT (Urolithin A) + FDA regulatory records (NMN).